• Thanks for stopping by. Logging in to a registered account will remove all generic ads. Please reach out with any questions or concerns.

Therapeutic Cannabis use

More trouble for the medical Cannabis users. Sounds like the QA is just not there.

https://beta.theglobeandmail.com/news/national/company-caught-selling-tainted-marijuana-cant-trace-source-of-contamination/article34144902/?ref=http%3A%2F%2Fwww.theglobeandmail.com&service=mobile

Company caught selling tainted marijuana can’t trace source of contamination



A federally regulated medical marijuana company caught selling products tainted with a banned pesticide that can cause debilitating health problems has been unable to determine how the chemical got into its supply, raising new questions about the oversight of the industry.

Organigram Inc. said on Monday that it has wrapped up an internal investigation into a product recall announced in December, but has turned up "inconclusive findings" with "no hard evidence leading to the source of the contamination."

The company also said it would offer full refunds to customers who purchased the tainted product, after initially refusing over the past two months to give patients their money back. The refunds will cost $2.26-million, Organigram said, which represents a significant financial hit to company. The writedown is worth slightly more than the total sales reported by Organigram in its most recent quarter.

The decision to refund customers' money comes as Organigram faces the prospect of a class-action lawsuit over the tainted cannabis, which some patients say has left them experiencing serious health affects, including lung problems, rashes, and persistent nausea and vomiting. At least two law firms are looking at launching actions that would force the company to surrender profits related to the tainted product.

Organigram is one of three medical marijuana companies caught up in a banned-pesticide scare that has swept through the medical marijuana industry and raised concerns about Health Canada's oversight of the sector – particularly as Ottawa prepares to legalize cannabis for recreational use, creating what is expected to be a highly lucrative business.

Mettrum Ltd., Organigram Inc., and Aurora Cannabis Inc. announced late last year that they were recalling products after the pesticide myclobutanil was discovered in medicine sold to clients. Myclobutanil is outlawed on plants that are smoked because it produces hydrogen cyanide when heated and can cause serious health problems.

Monday's announcement by Organigram that its investigation could not determine the source of the problem casts further doubt on the credibility of the industry, which is licensed by the federal government to produce safe, pharmaceutical products for patients who use the drug to treat everything from cancer-related pain to epilepsy.

Several patients who consumed the tainted cannabis say they are not sure if they can trust the products again, particularly since Health Canada does not require regular safety testing for all 38 companies in the industry to ensure the medicine is clean.

Organigram maintains it has never used myclobutanil which is known in the industry as an easy but dangerous shortcut to dealing with outbreaks of mildew that can threaten crops. The company said it believes the banned pesticide may have gotten into its plants through "inputs" in the growing process, such as contaminated fertilizer or soil. In particular, Organigram officials suspect peat moss the company used for a time in 2016 may have been treated with myclobutanil before entering the facility, but the company has no conclusive proof and no longer uses the peat moss.

"As a result of the contamination issue, the company has instituted a series of new protocols to prevent a recurrence of any issue of this nature," Organigram said. "All inputs from outside suppliers are now tested before they are used. Inputs include such things as seeds, growing medium, fertilizers, water, etc."

Organigram once marketed itself as an organic grower of cannabis but has since lost that designation from global certification body Ecocert and will have to reapply. The company said it is now testing all of its product lots for pesticides before they are sold.

The Globe and Mail first uncovered the myclobutanil problem in Canada's federally regulated medical marijuana industry in December, revealing that a recall at Mettrum was due to the pesticide. However, neither Health Canada nor the company included that information in their official public announcements of the recalls.

A day after The Globe article was published, Organigram issued a public notice saying it too had been found selling products that contained myclobutanil, which is well known throughout the industry as a banned product. The problem was discovered almost by accident when Aurora tested a bulk shipment it purchased from Organigram for resale to clients.

The myclobutanil scare exposed a troubling blind spot in Canada's regulatory regime. Health Canada said recently that it had not required the industry to test for harmful pesticides, because the companies know they were not allowed and therefore should not be using them.

Though only three companies have issued recalls, several patients told The Globe they now don't know which of the 38 federally licensed medical producers can be trusted, because there is no regular pesticide testing to prove that banned chemicals are not being used. Prior to the recent spate of recalls, each company claimed to be putting the health of their patients first and producing trustworthy products.

Since the recalls, Health Canada has mandated that Organigram and Mettrum, which has since been purchased by Canopy Growth Corp., begin testing all their products for pesticides. Health Canada has also said it would introduce random testing for pesticides for the whole industry.

However, some companies don't think those efforts are enough to win back the confidence of patients.

CanniMed Therapeutics Inc., based in Saskatoon, has taken the unusual step of commissioning independent lab tests on some of its products and making the data public to show consumers that its medicine contains no banned pesticides.

The move is an effort by the company to distance itself from the myclobutanil worries that now loom over the sector.

Myclobutanil is approved for use on some foods, such as berries and grapes, because the chemical can be safely metabolized by the digestive system. However, when smoked, it creates hydrogen cyanide that enters the bloodstream directly through the lungs. Its manufacturer, Dow AgroSciences, issued a statement last month saying that the product is not approved for cannabis.

Myclobutanil has long been a concern among illegal grow operations, since it is considered an easy but very dangerous shortcut to saving a crop hit by a mildew infestation. As illegal storefront cannabis dispensaries proliferated across Canada last year in advance of legalization, Health Canada warned consumers that dispensary product was risky and sought to steer patients towards the regulated industry instead.

Health Canada told The Globe in September it had a zero-tolerance policy for contaminants such as myclobutanil and would consider revoking a company's licence if they were found using it.

But since the pesticide was discovered in legally produced marijuana products, Health Canada and the companies involved have instead sought to play down the problem. Mettrum and OrganiGram told clients the chemical was approved for use on fruit, giving the impression of safety, while leaving out the details about what happens when myclobutanil is heated. Meanwhile, Health Canada referred to the residue detected as "trace amounts" that are "low risk."

But Warren Porter, a top U.S. toxicologist, has questioned Canada's response to the problem, saying Health Canada and the companies "have no idea whether or not that's true," because there is no scientific data to support those assurances.






 
In the end, it'll be up to Health Canada to get the regulations required in place. The community has know this for awhile and many have switched providers already. Hopefully, they'll have it sorted by the time that Trudeau legalizes it for the gen pop. If he ever does ::) Watch and shoot.
 
I think it was in Washington state there is a lot of work going on with different strains and they are working on doing actual studies on the different ratios of a lot of the different cannabinoids (vice just THC).  They are also working on developing some different ways to take it, like a time release dermal patch, or slow release oral pills.  Now that things are more out in the open, I think the knowledge will start to grow, although right now it mostly seems to be trial and error from the users passing on what strain works better for their particular disease/ailment, which is a start.

I think the recent supreme court decision on having the police be SMEs on determining if a driver is 'impaired' takes some of the need for a hard and fast limit on your bloodstream out of the equation.  It could equally apply to prescription medicine, being terribly tired, etc etc.  Could be prone to abuse, but makes sense in principle. I think generally people need to take responsibility for their own decisions; I know there have been days where I've been tired enough that after half a beer there was no way I was able to focus enough to be able to safely drive, even though I'm sure I was nowhere near the legal limit, so I just didn't. 
 
Medreleaf is my provider. Much of their product, including what I use comes from Tikun Olam from Israel. They are one of the world leaders in medical cannabis research. Israel is also way ahead of most in research into soldiers and PTSD treatment with cannabis.
http://www.tikunolam.com/mobile/contact.php
 
recceguy said:
Medreleaf is my provider. Much of their product, including what I use comes from Tikun Olam from Israel. They are one of the world leaders in medical cannabis research. Israel is also way ahead of most in research into soldiers and PTSD treatment with cannabis.
http://www.tikunolam.com/mobile/contact.php

MY LP as well phenomenal organization, and a leader in the industry.

dileas

tess
 
Tweed Main Street Sent me an email saying they are getting ready for legalization in canada and that to ensure they have supplies for us all the time, we get access to spectrum products. If we want their other products, they will have to be purchased as recreational. Whaaat?  I suspect other LP will follow suite? Thoughts?
 
This just out from a Senate subcommittee ...
More research is needed to assess changes to the policy governing veterans’ access to medical cannabis, the Senate’s Subcommittee on Veterans Affairs said in a report released Wednesday.

The Canadian Armed Forces demand a lot from its members. Two out of five veterans experience chronic pain. One out of five has depression, while almost as many live with post-traumatic stress disorder. Although medical research on the therapeutic value of cannabis is still in its infancy, the subcommittee heard that use of cannabis has had beneficial effects for many veterans and that the number of veterans using opioids dropped significantly as medical cannabis prescriptions rose.

In 2016, Veterans Affairs enacted a new policy reducing the amount of medical cannabis eligible for reimbursement to three grams a day from 10 grams. It also capped the reimbursement rate at $8.50 per gram. This came about after the Office of the Auditor General of Canada recommended that Veterans Affairs try to contain costs for the medical cannabis program, which had climbed from $400,000 in 2013-14 to over $12.1 million in 2015.

One psychiatrist told the subcommittee that patients who had been stable became symptomatic again after the three-gram limit was imposed, though other witnesses said the limit is appropriate. With regard to the reimbursement cap, witnesses noted that cannabis oils — which allow for more exact dosage — are priced above $8.50 per gram and that potent strains for relief of severe and chronic pain are also more expensive.

The subcommittee makes five recommendations, including that Veterans Affairs periodically examine the $8.50-per-gram reimbursement rate. The subcommittee also recommends that the federal government make significant investments in research on the use of medical cannabis and on its potential effect on veterans’ consumption of prescription pharmaceuticals so as to better inform Veterans Affairs policies regarding medical cannabis.

Quick Facts

    Between 1998 and 2015, 26% of regular force members were released from the Canadians Armed Forces for medical reasons.
    In 2016-17, Veterans Affairs spent $64 million on medical cannabis reimbursements — 5.7 million grams for 4,474 clients. After the new policy was implemented, spending dropped to $51 million in 2017-18 — but this paid for 6 million grams of cannabis for 7,298 clients.
    As of August 2018, Veterans Affairs Canada was reimbursing 8,175 veterans for medical cannabis.
    The Globe and Mail reported in May 2018 that 43% fewer veterans were using benzodiazepines (sedatives) and that 31% fewer were using opioids compared to 2012, when medical cannabis prescriptions spiked. Just a few days earlier, a Veterans Canada official had told the subcommittee that the department had found no decrease in the use of such drugs ...
Report downloadable @ link - here's the recommendations:
RECOMMENDATION 1:
That Veterans Affairs Canada improve its consultation mechanisms and use them more regularly to ensure greater and more transparent consultation of veterans and the professionals who work with them at all key stages of the development of new policies that affect them and to ensure that their experiences are genuinely considered in the department’s decision-making.

RECOMMENDATION 2:
That Veterans Affairs Canada periodically examine the effects of its maximum reimbursement rate of $8.50 per gram on veterans’ access to the various cannabis products, including by consulting with veterans who use cannabis and experts, to fully understand the barriers this limit may create and their impact on veterans’ health.

RECOMMENDATION 3:
That the Government of Canada quickly make significant investments in research on the use of cannabis for medical purposes, including:

    specific research on veterans’ use of cannabis for medical purposes; and
    examining the potential issues resulting from over usage, and that the gathered data be disseminated to the public and health professionals.

RECOMMENDATION 4:
That Veterans Affairs Canada undertake a detailed review of the potential impacts of medical cannabis use on Canadian veterans’ consumption of prescription pharmaceuticals and that the department publish the findings and an analysis of the net costs of cannabis reimbursements, taking into account the potential savings in reimbursements for other drugs.

RECOMMENDATION 5:
That Veterans Affairs Canada, in collaboration with Health Canada, consider taking measures to ensure the availability of cannabis to veterans who use it for medical purposes.
 
Back
Top